Lenvatinib

Generic Name
Lenvatinib
Brand Names
Lenvima 10, Kisplyx, Lenvima
Drug Type
Small Molecule
Chemical Formula
C21H19ClN4O4
CAS Number
417716-92-8
Unique Ingredient Identifier
EE083865G2
Background

Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as cell proliferation, migration, apoptosis and differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour growth and cancer progression. In particular, VEGF has been identified as a crucial regulator of both physiologic and pathologic angiogenesis and increased expression of VEGF is associated with a poor prognosis in many types of cancers.

Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer. Most patients with thyroid cancer have a very good prognosis with treatment (98% 5 year survival rate) involving surgery and hormone therapy. However, for patients with RAI-refractory thyroid cancer, treatment options are limited and the prognosis is poor, leading to a push for the development of more targeted therapies such as lenvatinib.

Indication

Lenvatinib is indicated for the treatment of the following cancerous conditions:

Differentiated Thyroid Cancer (DTC)

Renal Cell Carcinoma (RCC)

Hepatocellular Carcinoma (HCC)

Endometrial Carcinoma

Associated Conditions
Advanced Renal Cell Carcinoma, Endometrial Carcinoma, Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally advanced radioactive iodine-refractory Differentiated Thyroid Cancer (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Cancer (DTC)
Associated Therapies
-

Radiofrequency Ablation Combined With Toripalimab and Lenvatinib in the Treatment of Short-term Recurrent Hepatocellular Carcinoma.

First Posted Date
2021-12-17
Last Posted Date
2022-01-27
Lead Sponsor
Henan Cancer Hospital
Target Recruit Count
90
Registration Number
NCT05162898

A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma

First Posted Date
2021-12-13
Last Posted Date
2024-04-04
Lead Sponsor
Zhejiang University
Target Recruit Count
44
Registration Number
NCT05155189
Locations
🇨🇳

the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

🇨🇳

The first affiliated hospital of Zhengzhou University, Zhengzhou, China

A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma

First Posted Date
2021-12-07
Last Posted Date
2024-05-14
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
40
Registration Number
NCT05147558
Locations
🇺🇸

Memorial Sloan Kettering Bergen (Limited protocol activities), Montvale, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Westchester (Limited protocol activities), Harrison, New York, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 4 locations

Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

First Posted Date
2021-11-02
Last Posted Date
2024-07-08
Lead Sponsor
Emory University
Target Recruit Count
19
Registration Number
NCT05103904
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

🇺🇸

Mayo Clinic Arizona, Scottsdale, Arizona, United States

Cryoablation Combined With Sintilimab Plus Lenvatinib In Previously Treated Unresectable Liver Metastasis From Solid Tumors

First Posted Date
2021-10-28
Last Posted Date
2022-11-10
Lead Sponsor
Fudan University
Target Recruit Count
25
Registration Number
NCT05098847
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

First Posted Date
2021-10-25
Last Posted Date
2024-10-24
Lead Sponsor
Eisai Inc.
Target Recruit Count
89
Registration Number
NCT05091346
Locations
🇺🇸

Icahn School of Medicine at Mount Sinai, New York, New York, United States

🇺🇸

Emory University, Atlanta, Georgia, United States

🇺🇸

Providence Medical Center, Portland, Oregon, United States

and more 30 locations

Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors

Phase 1
Active, not recruiting
Conditions
Interventions
First Posted Date
2021-10-18
Last Posted Date
2024-10-01
Lead Sponsor
EMD Serono Research & Development Institute, Inc.
Target Recruit Count
50
Registration Number
NCT05081180
Locations
🇨🇦

CHU Sainte-Justine, Montréal, Canada

🇨🇦

The Hospital for Sick Children, Toronto, Canada

🇫🇷

CHU Angers - Hôpital Hôtel Dieu - Service de Cancérologie Pédiatrique, Angers Cedex 9, France

and more 6 locations

A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients

Phase 2
Conditions
Interventions
First Posted Date
2021-10-15
Last Posted Date
2021-12-08
Lead Sponsor
Shanghai Chest Hospital
Target Recruit Count
35
Registration Number
NCT05078931
Locations
🇨🇳

Department of Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

Phase 2
Recruiting
Conditions
Interventions
First Posted Date
2021-10-01
Last Posted Date
2024-11-20
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
104
Registration Number
NCT05064280
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath